TdLN‐TTSM cells are deemed to be the responders to PD‐1/PD‐L1 blockade therapy.[59] Since the combined treatment can promote the differentiation of TTSM cells, it theoretically stands to enhance the efficacy of tumor immunotherapy based on PD‐1 blockade. Here, CD274 is linked to neoplasm.